Table 4.
Cox Proportional Hazard Regression Analysis to Identify Risk Factors Related to Thrombocytosis After 12 Months of Treatment
| Factors | Thrombocytosis (n=375) | Normal (n=4820) | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | ||||||||
| <30 | 195 | 52 | 2433 | 50.5 | Ref | – | ||
| ≥30 | 180 | 48 | 2387 | 49.5 | 0.897(0.733, 1.099) | 0.295 | ||
| Sex | ||||||||
| Male | 333 | 88.8 | 4654 | 96.6 | Ref | – | Ref | – |
| Female | 42 | 11.2 | 166 | 3.4 | 2.746(1.992, 3.786) | <0.001 | 3.422(2.418, 4.843) | <0.001 |
| Transmission route | ||||||||
| Homosexual | 282 | 75.2 | 3908 | 81.1 | Ref | – | ||
| Heterosexual | 66 | 17.6 | 551 | 11.4 | 1.640(1.254, 2.143) | <0.001 | ||
| Other/unknown | 27 | 7.2 | 361 | 7.5 | 1.043(0.702, 1.547) | 0.836 | ||
| WHO clinical stage | ||||||||
| I–II | 344 | 91.7 | 4352 | 90.3 | Ref | – | ||
| III–IV | 23 | 6.1 | 388 | 8.0 | 0.674(0.442, 1.029) | 0.067 | ||
| BMI (kg/m2) | ||||||||
| 18.5–24.0 | 173 | 46.1 | 2503 | 51.9 | Ref | – | Ref | – |
| < 18.5 | 23 | 6.1 | 354 | 7.3 | 0.995(0.618, 1.475) | 0.835 | 0.984(0.636, 1.524) | 0.943 |
| >24.0 | 96 | 25.6 | 887 | 18.4 | 1.437(1.119, 1.844) | 0.004 | 1.472(1.145, 1.894) | 0.003 |
| HBsAg | ||||||||
| Negative | 352 | 93.9 | 4494 | 93.2 | Ref | – | ||
| Positive | 17 | 4.5 | 258 | 5.4 | 0.785(0.482, 1.277) | 0.329 | ||
| Anti-HCV | ||||||||
| Negative | 367 | 97.9 | 4639 | 96.2 | Ref | – | ||
| Positive | 4 | 1.1 | 100 | 2.1 | 0.462(0.173, 1.238) | 0.125 | ||
| Syphilis | ||||||||
| Negative | 241 | 64.3 | 3008 | 62.4 | Ref | – | ||
| Positive | 113 | 30.1 | 1617 | 33.5 | 0.847(0.678, 1.059) | 0.146 | ||
| Baseline VL (copies/mL) | ||||||||
| <100,000 | 248 | 66.1 | 3312 | 68.7 | Ref | – | ||
| ≥100,000 | 119 | 31.7 | 1361 | 28.2 | 1.097(0.882, 1.366) | 0.405 | ||
| Baseline CD4 count (×109 /L) | ||||||||
| <350 | 205 | 54.7 | 2862 | 59.4 | Ref | – | ||
| ≥350 | 164 | 43.7 | 1900 | 39.4 | 1.214(0.989, 1.491) | 0.064 | ||
| Baseline CD4/CD8 ratio | ||||||||
| <0.4 | 267 | 71.2 | 3329 | 69.1 | Ref | – | ||
| ≥0.4 | 95 | 25.3 | 1351 | 28.0 | 0.943(0.746, 1.192) | 0.626 | ||
| CD4 count at 1 year of ART (×109 /L) | ||||||||
| <350 | 73 | 19.5 | 1014 | 21.0 | Ref | – | ||
| ≥350 | 226 | 60.3 | 2781 | 57.7 | 1.150(0.884, 1.496) | 0.297 | ||
| WBC (×109 /L) | ||||||||
| ≥4.0 | 342 | 91.2 | 4196 | 87.1 | Ref | – | Ref | – |
| <4.0 | 33 | 8.8 | 624 | 12.9 | 0.634(0.443, 0.906) | 0.012 | 0.537(0.349, 0.824) | 0.004 |
| HGB (g/L) | ||||||||
| ≥110(Female) or ≥120(Male) | 348 | 92.8 | 4506 | 93.5 | Ref | – | ||
| <110(Female) or >120(Male) | 27 | 7.2 | 314 | 6.5 | 1.032(0.697, 1.526) | 0.876 | ||
| NLR | ||||||||
| <2.0 | 237 | 63.2 | 2867 | 59.5 | Ref | – | ||
| 2.0–4.0 | 101 | 26.9 | 1460 | 30.3 | 0.863(0.682, 1.090) | 0.216 | ||
| >4.0 | 31 | 8.3 | 369 | 7.7 | 1.060(0.733, 1.534) | 0.755 | ||
Notes: Data are presented as n (%), or median (interquartile range). Variable had missing values: WHO clinical stage = 88; BMI = 1159; HBV = 74; HCV =85; Syphilis = 216; VL = 155; CD4 count = 64; CD4/CD8 ratio = 153; CD4 count at 1 year of ART = 1101; NLR = 130.
Abbreviations: HR, hazard ratio; CI, confidence interval; WHO, world health organization; BMI, body mass index; HBsAg, hepatitis B surface antigen; Anti-HCV, antibody to hepatitis C virus; VL, viral load; WBC, white blood cell; HGB, haemoglobin; NLR, neutrophil-lymphocyte ratio.